Cellectis (NASDAQ: CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The company is engaged in developing a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of experience in genome engineering based on its flagship TALEN® products and meganucleases as well as its pioneering electroporation PulseAgile technology, to create a new generation of immunotherapies. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. For more information, visit the company’s website at www.cellectis.com.
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer